Lack of Correlation Between Serum Soluble Fas/APO-1 Levels and Autoimmune Disease

Overview

Journal Arthritis Rheum

Specialty Rheumatology

Date 1995 Dec 1

PMID 8849345

Citations 7

Authors

N Goel

D T Ulrich

E W St Clair

J A Fleming

D H Lynch

M F Seldin

Affiliations

Soon will be listed here.

Abstract

Objective: To determine whether elevated soluble Fas/APO-1 (sFas/APO-1) levels are associated with either autoimmune disease or evidence of flares in autoimmune disease.

Methods: Thirty-seven serum samples were retrospectively obtained from normal controls and patients with laboratory evidence of autoimmune disease activity. These samples were assayed for sFas/APO-1 levels by an enzyme-linked immunosorbent assay, and hospital medical records were retrospectively reviewed for clinical and laboratory characteristics of the patients.

Results: Soluble Fas/APO-1 levels did not correlate with clinical diagnoses or laboratory abnormalities. The mean and range of sFas/APO-1 levels were similar in systemic lupus erythematosus patients (including those with active disease), patients with other autoimmune diseases, and normal controls.

Conclusion: These data strongly suggest that measurement of sFas/APO-1 levels is unlikely to hold clinical value or play a role in the pathogenesis of autoimmune disease.

Citing Articles

The levels of serum-soluble Fas in patients with rheumatoid arthritis and systemic sclerosis.

Ates A, Kinikli G, Turgay M, Duman M Clin Rheumatol. 2004; 23(5):421-5.

PMID: 15459814 DOI: 10.1007/s10067-004-0909-4.

Serum sFAS levels are elevated in ANCA-positive vasculitis compared with other autoimmune diseases.

Christensson M, Pettersson E, Eneslatt K, Christensson B, Bratt J, Rantapaa-Dahlqvist S J Clin Immunol. 2002; 22(4):220-7.

PMID: 12148596 DOI: 10.1023/a:1016040925295.

Soluble CD95 concentrations are increased in patients with severe systemic lupus erythematosus, but not in their first degree relatives.

van der Linden M, van Lopik T, Aarden L, Westendorp R, Huizinga T Ann Rheum Dis. 2001; 60(3):237-41.

PMID: 11171685 PMC: 1753586. DOI: 10.1136/ard.60.3.237.

Serum soluble Fas/APO-1 is increased in patients with primary Sjögren's syndrome.

Fujihara T, Takeuchi T, Tsubota K, Kayagaki N, Yagita H, Okumura K Clin Rheumatol. 1999; 17(6):496-9.

PMID: 9890678 DOI: 10.1007/BF01451286.

Elevated soluble Fas/APO-1 (CD95) levels in silicosis patients without clinical symptoms of autoimmune diseases or malignant tumours.

Tomokuni A, Aikoh T, Matsuki T, Isozaki Y, Otsuki T, Kita S Clin Exp Immunol. 1997; 110(2):303-9.

PMID: 9367417 PMC: 2265505. DOI: 10.1111/j.1365-2249.1997.tb08332.x.